Sensei Biotherapeutics to Participate in Jefferies Healthcare Conference
Sensei Biotherapeutics, a leader in immunotherapy, announced that CEO John Celebi will present at the Jefferies Healthcare Conference on June 8, 2022, at 3:00 p.m. ET, both in-person and virtually in New York, NY. Investors can access a live webcast of the presentation on the company's website, with a replay available for 90 days afterward. Sensei focuses on developing innovative cancer therapies, utilizing its TMAb™ and ImmunoPhage™ platforms. Their lead therapeutic candidate, SNS-101, targets the VISTA checkpoint to enhance T cell activity in the tumor microenvironment.
- None.
- None.
BOSTON, May 25, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced that John Celebi, president and chief executive officer, will present at the Jefferies Healthcare Conference, being held in New York, NY and virtually, on Wednesday, June 8, 2022 at 3:00 p.m. ET.
A webcast of Sensei’s presentation will be available in the Investors section of the Sensei website. A replay of the webcast will be on the website for approximately 90 days following the event. Registration for the live webcast is available here.
About Sensei Biotherapeutics
Sensei Biotherapeutics (NASDAQ: SNSE) is an immuno-oncology company that focuses on overturning the body’s tolerance of cancer cells and directing its defenses against them. Sensei has developed two unique approaches to develop highly selective therapeutics – its TMAb™ (Tumor Microenvironment Activated biologics) platform, which disables checkpoints and other immunosuppressive signals in the tumor microenvironment to unleash existing T cells against tumors, and the ImmunoPhage™ platform, which trains new T cells to recognize and kill malignant cells. Using its TMAb platform, the company is developing SNS-101, a fully human antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively only within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. The company is also using its platforms to develop preclinical programs targeting multiple solid tumor indications. For more information, please visit www.senseibio.com, and follow the company on Twitter @SenseiBio and LinkedIn.
Investor Contact:
Erin Colgan
Chief Financial Officer
Sensei Biotherapeutics
ecolgan@senseibio.com
Media Contact:
Chris Railey
Ten Bridge Communications
chris@tenbridgecommunications.com
FAQ
When will Sensei Biotherapeutics present at the Jefferies Healthcare Conference?
How can I watch the Sensei Biotherapeutics presentation?
What is the ticker symbol for Sensei Biotherapeutics?
What are the main platforms used by Sensei Biotherapeutics?
What is the purpose of SNS-101 developed by Sensei Biotherapeutics?
